Against the background of a global public health crisis and in the immediate aftermath of a game-changing US Presidential election, the FT Global Pharmaceutical and Biotechnology Conference agenda will provide an opportune moment to analyse the implications of these momentous events for the industry’s on-going transformation.
Oncology and beyond: how sustainable is the industry's current concentration on oncology and rare diseases?
Coronavirus: a 21st century case study of pharma and health
The changing power structure of the industry - how is the pharma innovation model evolving?
The million dollar question - how do we pay for cures?
Are manufacturing and supply chains the new competitive edge for pharma?
Head of Market Access, CSL Behring
“Broad themes covered from a wide range of stakeholders.”